Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
121-140 of 2,251 trials

Marginal Zone Lymphoma: Mosunetuzumab-Lenalidomide Study

We are investigating whether the combination of Mosunetuzumab and Lenalidomide is more effective than standard treatments for patients with relapsed or refractory Marginal Zone Lymphoma. The study aims to assess how well this new treatment works and its safety.

Marginal Zone Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Myeloma: [68Ga]Ga-PentixaFor PET Imaging Study

We are studying a new imaging method to see how accurately it detects myeloma at the beginning of treatment. This may help improve risk assessment and disease management for patients.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Psilocybin for Hospitalized Patients with Treatment-Resistant Depression

We are studying the safety and feasibility of psilocybin-assisted psychotherapy for patients with treatment-resistant depression in a hospital setting. This research aims to explore its effects on depression and the overall experience of patients.

Treatment-Resistant DepressionEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemotePsychiatry

Remifentanil for Intubation in Newborns

We are studying the best dose of remifentanil to safely sedate newborns during intubation. Our goal is to ensure effective sedation with minimal side effects.

Stable Neonates Requiring Intubation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Leukemia and Lymphoma: Dasatinib and Venetoclax Study for Children

We are testing two new drugs for children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. The goal is to assess safety and see if these drugs can effectively treat their condition.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Leukemia and Lymphoma: Ruxolitinib and Venetoclax Study

We are studying the safety and effectiveness of ruxolitinib and venetoclax in children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. This research aims to find better treatment options for these young patients.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Hematological Cancers in Children: New Drug Combination Study

We are testing a combination of Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for children with relapsed or refractory hematological malignancies. The goal is to assess safety and see if it works for patients with specific genetic changes.

Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Generalized Myasthenia Gravis: Ravulizumab for Kids

We are studying the effects of Ravulizumab in children with Generalized Myasthenia Gravis to see how well it works and its safety. This trial will help us understand if it improves their quality of life.

Generalized Myasthenia Gravis3-6 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Prostate Cancer Imaging: PSMA-PET vs. mpMRI

We are comparing two imaging methods to see which better identifies critical areas in high-risk prostate cancer. This study may help improve diagnosis and treatment planning for patients.

Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyUrology

Prostate Cancer: Apalutamide with Radiation Therapy

We are studying whether adding stereotactic body radiation therapy to Apalutamide improves treatment outcomes for men with low burden metastatic hormone-sensitive prostate cancer. This trial compares standard treatment alone to the combination therapy.

Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Ovarian Cancer: REGN5668 with Cemiplimab or REGN4018

We are studying the safety and effectiveness of REGN5668 when given with either Cemiplimab or REGN4018 for patients with ovarian cancer. This trial aims to find the best dose and see how well these combinations work.

Fallopian Tube CancerPrimary Peritoneal CancerOvarian CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Abdominal Aortic Aneurysm: Stem Cell Treatment Study

We are testing whether injecting stem cells into the aneurysm sac is safe and effective for patients undergoing endovascular repair. This study compares outcomes with those from traditional treatment methods.

Abdominal Aortic Aneurysm1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyInternal MedicineOrthopedics and Traumatology

Roxadustat for Anemia in Children with Chronic Kidney Disease

We are studying a new treatment for anemia in children and adolescents with chronic kidney disease. The trial will evaluate its effectiveness, safety, and how it impacts daily life.

Nephrogenic Anemia1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyNephrology

Acute Myeloid Leukemia: Hydroxyurea and Valproic Acid Study

We are investigating a new treatment combination for patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who cannot receive standard chemotherapy. The study will assess safety, effectiveness, and quality of life.

Acute Myeloid Leukemia6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Advanced Dedifferentiated Liposarcoma: Pemigatinib and Retifanlimab Study

We are studying the effects of two medications on patients with advanced dedifferentiated liposarcoma. The goal is to see if they improve treatment outcomes and quality of life.

Dedifferentiated Liposarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Isolated MMA: Long-Term Study of mRNA-3705

We are evaluating the long-term safety and effects of mRNA-3705 in individuals with Isolated MMA who have participated in earlier studies. This research aims to understand how the treatment impacts health and daily activities over time.

Methylmalonic AciduriaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal Medicine

Oxygen Therapy for AECOPD: Standard vs Targeted Approach

We are investigating whether a targeted oxygen therapy can reduce mortality and improve breathing in patients with acute exacerbations of chronic obstructive pulmonary disease. This study compares it to standard oxygen treatment to see which is more effective.

COPD Exacerbation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicinePulmonology

Kidney Transplant: Comparing rATG and Basiliximab

We are studying whether rATG is more effective than basiliximab in preventing kidney transplant rejection in sensitized patients without pre-existing antibodies. This trial aims to improve outcomes for kidney transplant recipients.

Kidney Transplant>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesNephrology

Osteoarthritis: Walking Rehabilitation with Anti-Inflammatory Treatment

We are exploring how a specific anti-inflammatory medication can support a walking rehabilitation program for people with hip or knee osteoarthritis. The goal is to see if this combination improves walking ability and overall comfort.

Osteoarthritis of the Hip or Knee≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineRheumatology

Acute Myeloid Leukemia: Comparing Treatment Regimens

We are studying two different conditioning regimens for adults with acute myeloid leukemia before stem cell transplantation. The goal is to see which regimen may improve survival and recovery outcomes.

Acute Myeloid Leukemia in Remission>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology